The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer.
 
Taro Mizuno
No Relationships to Disclose
 
Yukiya Narita
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Yasunobu Ishizuka
No Relationships to Disclose
 
Tomoki Sakakida
No Relationships to Disclose
 
Kazunori Honda
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takata; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Hiroya Taniguchi
Honoraria - Amgen; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Yakuhin; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Masashi Ando
Speakers' Bureau - Eisai; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masahiro Tajika
Speakers' Bureau - Bristol-Myers Squibb Japan; Otsuka
Research Funding - Pfizer (Inst)
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)